Evaxion launches enhanced AI immunology platform for vaccine antigen prediction Page 1

• The new version 5.0 of the AI ​​model EDEN has a novel toxin antigen predictor, is trained on an extended dataset and includes an advanced protein prediction function
• The launch is expected to enhance Evaxion's ability to quickly and effectively develop new AI-based vaccines and further cement strong interest in AI immunology from potential partners.
• New data demonstrates improved performance of EDEN is presented today in European Conference on Computational Biology in Turku, Finland

COPENHAGEN, Denmark, Sept. 19, 2024 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company focused on developing AI immunology-driven vaccines, is launching an enhanced version of its clinically validated AI immunology platform with an update to its EDEN AI prediction model. Among other improvements, the model can now predict toxin antigens, enabling the development of improved bacterial vaccines.

Bacterial toxins are often the main causes of disease, making their neutralization essential for developing effective vaccines. The improved EDEN model improves bacterial toxin prediction for vaccine development. With increased speed and accuracy, Evaxion can quickly identify the critical toxin targets to include in vaccines.

“Today’s launch of the enhanced EDEN AI prediction model is an important milestone for Evaxion and further strengthens our AI immunology platform. As one of the few truly AI-focused TechBio companies, our AI immunology platform is at the forefront of innovation and we will continue to invest in its development and refinement to further enhance our ability to discover new targets and develop advanced vaccines,” says Christian Kanstrup, CEO of Evaxion.

The AI ​​Immunology Platform uses advanced AI and machine learning technologies to design and develop new vaccine candidates that address significant unmet needs. Its AI prediction models are applied in cancer and infectious diseases and are scalable to other therapeutic areas. The platform can deliver a new target in as little as 24 hours, compared to years using traditional methods, and is independent of the delivery modality. The AI ​​Immunology Platform's prediction capabilities are robustly validated, as the target's predictive value has been shown to correlate with preclinical and clinical outcomes.